<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ivm</journal-id><journal-title-group><journal-title xml:lang="ru">Международный вестник ветеринарии</journal-title><trans-title-group xml:lang="en"><trans-title>International Journal of Veterinary Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-2419</issn><publisher><publisher-name>SpbGUVM Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52419/issn2072-2419.2024.1.403</article-id><article-id custom-type="elpub" pub-id-type="custom">ivm-1348</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НЕЗАРАЗНЫЕ БОЛЕЗНИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NON-COMMUNICABLE DISEASE</subject></subj-group></article-categories><title-group><article-title>Актуальность лечения опухолей легкого у мелких домашних животных и перспективы применения таргентной терапии при EGFR и ALK/ROS1 мутациях на примере клинических данных гуманной и ветеринарной медицины</article-title><trans-title-group xml:lang="en"><trans-title>The relevance of the treatment of lung tumors in small domestic animals and the prospects for the use of targeted therapy for EGFR and ALK/ROS1 mutations on the example of clinical data from humane and veterinary medicine</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0149-9360</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семенов</surname><given-names>Б. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Semenov</surname><given-names>B. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д-р ветеринар. наук, профессор, проф. каф. общей, частной и оперативной хирургии</p></bio><bio xml:lang="en"><p>Doctor of Veterinary Sciences, Professor, Professor of the Department of Surgery </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4726-6204</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Назарова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Nazarova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> канд. ветеринар. наук, асс. каф. общей, частной и оперативной хирургии</p></bio><bio xml:lang="en"><p>Candidate of Veterinary Sciences, Assistant of the Department of Surgery </p></bio><email xlink:type="simple">anna.v.nazarova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8981-0696</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузнецова</surname><given-names>Т. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuznetsova</surname><given-names>T. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p> канд. биол. наук, доц. каф. генетических и репродуктивных биотехнологий</p></bio><bio xml:lang="en"><p>Candidate of Biological Sciences, docent of the Department of Genetic and  Reproductive Biotechnologies </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-4166-662X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колодяжный</surname><given-names>П. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolodyazhny</surname><given-names>P. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> студ.</p></bio><bio xml:lang="en"><p> student </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный университет ветеринарной медицины»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>St. Petersburg State University of Veterinary Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>02</day><month>04</month><year>2024</year></pub-date><volume>0</volume><issue>1</issue><fpage>403</fpage><lpage>414</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Семенов Б.С., Назарова А.В., Кузнецова Т.Ш., Колодяжный П.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Семенов Б.С., Назарова А.В., Кузнецова Т.Ш., Колодяжный П.А.</copyright-holder><copyright-holder xml:lang="en">Semenov B.S., Nazarova A.V., Kuznetsova T.S., Kolodyazhny P.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vetjournal.spbguvm.ru/jour/article/view/1348">https://vetjournal.spbguvm.ru/jour/article/view/1348</self-uri><abstract><p>В период с 2020 по 2023 год проведено ретроспективное исследование историй болезней животных с опухолями в легких. В исследование включены 43 животных (15 собак и 28 кошек). Новообразования выявлялись с помощью методов инструментальной диагностики и морфологических исследований. Злокачественные опухоли легкого имеют различную гистологическую структуру, различаются по клиническому течению и результатам лечения. Хирургическое вмешательство является методом выбора для собак и кошек с первичными опухолями легких. У человека хирургический метод является одним из основных методов лечения рака легкого (РЛ). Поскольку в 70% случаев РЛ развивается без клинических признаков, большинство случаев опухолей трахеи, бронхов и легкого выявляются на IV стадии не только у животных, но и у человека, что делает невозможном излечивающее хирургическое вмешательство. Параллельно совершенствуются методы молекулярной биологии. Это приводит к разработке новых методов лечения, основанных на применении более эффективных противоопухолевых препаратов. Одним из современных методов лечения рака является таргетная терапия. Молекулярно-ориентированные препараты блокируют рост раковых клеток с помощью вмешательства в механизм действия конкретных целевых (таргетных) молекул, необходимых для канцерогенеза и роста опухоли. В ветеринарной медицине в основном применяются хирургический и химиотерапевтический методы лечения, при этом последний не показывает достаточной эффективности. При этом в гуманной медицине для лечения рака легкого широко применяется таргетная терапия, действие которой отличается большей точностью и эффективностью. В доступной литературе не так много информации о применении таргетной терапии у животных и практически нет исследований по лечению неоперабельного РЛ у кошек, что делает актуальным проведение клинических исследований по применению таргетных препаратов у мелких домашних животных.</p></abstract><trans-abstract xml:lang="en"><p>In the period from 2020 to 2023 was conducted a retrospective study of animal disease histories with lung neoplasia. 43 animals (15 dogs and 28 cats) were included in the study. Neoplasms were identified by instrumental and histopathological methods. Malignant lung tumors have different histological structure, differ in clinical course and treatment results. Surgery is the method of choice for dogs and cats with primary lung tumors. In humans, the surgical method is one of the main methods of treating lung cancer (LC). Since in 70% of cases LC develops without clinical signs, most cases of the trachea, bronchi and lung tumors are detected at IV stage not only in animals, but also in humans, which makes radical surgery impossible. The development of molecular biology methods leads to the development of new treatment methods based on the use of more effective antitumor drugs. One of the innovative methods of cancer treatment is targeted therapy. Molecular-oriented drugs block the growth of cancer cells by interfering with the mechanism of action of specific target molecules necessary for carcinogenesis and tumor growth. In veterinary medicine, surgical and chemotherapeutic methods of treatment are mainly used, while the latter does not show sufficient effectiveness. At the same time, in humane medicine for the treatment of lung cancer widely use targeted therapy, the effect of which is more accurate and effective. There is not much information in the available literature on the use of targeted therapy in animals and there are practically no studies on the treatment of inoperable LC in cats, which makes it relevant to conduct clinical studies on the use of targeted drugs in companion animals.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>опухоль лёгкого</kwd><kwd>рак лёгкого</kwd><kwd>химиотерапия</kwd><kwd>таргетная терапия</kwd><kwd>мутации EGFR</kwd><kwd>транслокации ALK и ROS1</kwd><kwd>ингибиторы EGFR/ALK/ROS1/MET</kwd><kwd>собаки</kwd><kwd>кошки</kwd></kwd-group><kwd-group xml:lang="en"><kwd>lung neoplasia</kwd><kwd>lung cancer</kwd><kwd>chemotherapy</kwd><kwd>targeted therapy</kwd><kwd>EGFR mutation</kwd><kwd>ALK and ROS1 translocation</kwd><kwd>inhibitors of EGFR/ALK/ROS1/MET</kwd><kwd>dogs</kwd><kwd>cats</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Быченко, Д. Современные методы диагностики, лечения и степень выживаемости при первичной неоплазии легких у собак / Д. Быченко, Е. Д. Зиньков // Наукоёмкие исследования как основа инновационного развития общества: сборник статей Международной научно-практической конференции, Калуга, 27 ноября 2021 года. – Уфа: Общество с ограниченной ответственностью "ОМЕГА САЙНС", 2021. – С. 280-283.</mixed-citation><mixed-citation xml:lang="en">Bychenko, D. Modern methods of diagnosis, treatment and degree of survival in primary lung neoplasia in dogs / D. Bychenko, E. D. Zinkov // High-tech research as a basis for innovative development of society: collection of articles of the International scientific and practical Conference, Kaluga, November 27, 2021. – Ufa: OMEGA SCIENCES Limited Liability Company, 2021. – pp. 280-283.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Реутова, Е. В., Лактионов К. П., Юдин Д. И., Ардзинба М. С. Рациональный подход к терапии EGFR-позитивного рака легкого // МС. 2019. №19. URL: https://cyberleninka.ru/article/n/ratsionalnyypodhod-k-terapii-egfr-pozitivnogo-rakalegkogo (дата обращения: 23.02.2024).</mixed-citation><mixed-citation xml:lang="en">Reutova, Е. V., Laktionov К. Р., Yudin D. I., Ardzinba М. S. Rational approach to the treatment of EGFR-positive lung cancer // МС. 2019, 19. URL: https://cyberleninka.ru/article/n/ratsionalnyy-podhod-k-terapii-egfrpozitivnogo-raka-legkogo (дата обращения: 23.02.2024).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">McPhetridge JB, Scharf VF, Regier PJ, Toth D, Lorange M, Tremolada G, Dornbusch JA, Selmic LE, Bae S, Townsend KL, McAdoo JC, Thieman KM, Solari F, Walton RA, Romeiser J, Tuohy JL, Oblak ML. Distribution of histopathologic types of primary pulmonary neoplasia in dogs and outcome of affected dogs: 340 cases (2010-2019). J Am Vet Med Assoc. 2021 Nov 30;260(2):234-243. doi: 10.2460/javma.20.12.0698.</mixed-citation><mixed-citation xml:lang="en">McPhetridge JB, Scharf VF, Regier PJ, Toth D, Lorange M, Tremolada G, Dornbusch JA, Selmic LE, Bae S, Townsend KL, McAdoo JC, Thieman KM, Solari F, Walton RA, Romeiser J, Tuohy JL, Oblak ML. Distribution of histopathologic types of primary pulmonary neoplasia in dogs and outcome of affected dogs: 340 cases (2010-2019). J Am Vet Med Assoc. 2021 Nov 30;260(2):234-243. doi: 10.2460/javma.20.12.0698.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Семенкин, А. А., Сапроненко В. С., Логинова Е. Н., Надей Е. В. Таргетная терапия в онкологии // ЭиКГ. 2022. №9 (205). URL: https://cyberleninka.ru/article/n/targetnaya-terapiya-v-onkologii (дата обращения: 23.02.2024).</mixed-citation><mixed-citation xml:lang="en">Semenkin A. A., Sapronenko V. S., Loginova E. N., Nadey E. V. Targeted therapy in oncology. Experimental and Clinical Gastroenterology. 2022;205(9): 222–228. (In Russ.) DOI: 10.31146/1682-8658-ecg-205-9-222-228.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ichimata Masanao Prognosis of primary pulmonary adenocarcinoma after surgical resection in small-breed dogs: 52 cases (2005-2021) May 2023 Journal of Veterinary Internal Medicine 37(4)</mixed-citation><mixed-citation xml:lang="en">Ichimata Masanao Prognosis of primary pulmonary adenocarcinoma after surgical resection in small-breed dogs: 52 cases (2005-2021) May 2023 Journal of Veterinary Internal Medicine 37(4) DOI:10.1111/jvim.16739</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kobayashi K, Takemura RD, Miyamae J, Mitsui I, Murakami K, Kutara K, Saeki K, Kanda T, Okamura Y, Sugiyama A. Phenotypic and molecular characterization of novel pulmonary adenocarcinoma cell lines established from a dog. Sci Rep. 2023 Oct 5;13 (1):16823.</mixed-citation><mixed-citation xml:lang="en">Kobayashi K, Takemura RD, Miyamae J, Mitsui I, Murakami K, Kutara K, Saeki K, Kanda T, Okamura Y, Sugiyama A. Phenotypic and molecular characterization of novel pulmonary adenocarcinoma cell lines established from a dog. Sci Rep. 2023 Oct 5;13 (1):16823.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Dai T, Jiang W, Wang M, Guo Z, Dai R. Influence of two-period cross-over design on the bioequivalence study of gefitinib tablets in beagle dogs. Eur J Pharm Sci. 2021 Oct 1;165:105933. doi: 10.1016/j.ejps.2021.105933.</mixed-citation><mixed-citation xml:lang="en">Dai T, Jiang W, Wang M, Guo Z, Dai R. Influence of two-period cross-over design on the bioequivalence study of gefitinib tablets in beagle dogs. Eur J Pharm Sci. 2021 Oct 1;165:105933. doi: 10.1016/j.ejps.2021.105933.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Carter J, Tadi P. Erlotinib. 2022 Dec 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan– PMID: 32119371.</mixed-citation><mixed-citation xml:lang="en">Carter J, Tadi P. Erlotinib. 2022 Dec 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan– PMID: 32119371.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Adachi K, Mizoguchi K, Kawarada S, Miyoshi A, Suzuki M, Chiba S, Deki T. Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats. J Toxicol Sci. 2010 Aug;35 (4):503-14. doi: 10.2131/jts.35.503.</mixed-citation><mixed-citation xml:lang="en">Adachi K, Mizoguchi K, Kawarada S, Miyoshi A, Suzuki M, Chiba S, Deki T. Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats. J Toxicol Sci. 2010 Aug;35 (4):503-14. doi: 10.2131/jts.35.503.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Jung S. Presumed erlotinib-induced bilateral corneal ulcers in a dog with lung tumor. Vet Ophthalmol. 2023 Jan;26(1):78-80. doi: 10.1111/vop.13034.</mixed-citation><mixed-citation xml:lang="en">Jung S. Presumed erlotinib-induced bilateral corneal ulcers in a dog with lung tumor. Vet Ophthalmol. 2023 Jan;26(1):78-80. doi: 10.1111/vop.13034.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Timmermans-Sprang EPM, Mestemaker HM, Steenlage RR, Mol JA. Dasatinib inhibition of cSRC prevents the migration and metastasis of canine mammary cancer cells with enhanced Wnt and HER signalling. Vet Comp Oncol. 2019 Sep;17(3):413-426. doi: 10.1111/vco.12490.</mixed-citation><mixed-citation xml:lang="en">Timmermans-Sprang EPM, Mestemaker HM, Steenlage RR, Mol JA. Dasatinib inhibition of cSRC prevents the migration and metastasis of canine mammary cancer cells with enhanced Wnt and HER signalling. Vet Comp Oncol. 2019 Sep;17(3):413-426. doi: 10.1111/vco.12490.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Colclough N, Chen K, Johnström P, Strittmatter N, Yan Y, Wrigley GL, Schou M, Goodwin R, Varnäs K, Adua SJ, Zhao M, Nguyen DX, Maglennon G, Barton P, Atkinson J, Zhang L, Janefeldt A, Wilson J, Smith A, Takano A, Arakawa R, Kondrashov M, Malmquist J, Revunov E, VazquezRomero A, Moein MM, Windhorst AD, Karp NA, Finlay MRV, Ward RA, Yates JWT, Smith PD, Farde L, Cheng Z, Cross DAE. Preclinical Comparison of the Bloodbrain barrier Permeability of Osimertinib with Other EGFR TKIs. Clin Cancer Res. 2021 Jan 1;27(1):189-201. doi: 10.1158/1078-0432.CCR-19-1871.</mixed-citation><mixed-citation xml:lang="en">Colclough N, Chen K, Johnström P, Strittmatter N, Yan Y, Wrigley GL, Schou M, Goodwin R, Varnäs K, Adua SJ, Zhao M, Nguyen DX, Maglennon G, Barton P, Atkinson J, Zhang L, Janefeldt A, Wilson J, Smith A, Takano A, Arakawa R, Kondrashov M, Malmquist J, Revunov E, VazquezRomero A, Moein MM, Windhorst AD, Karp NA, Finlay MRV, Ward RA, Yates JWT, Smith PD, Farde L, Cheng Z, Cross DAE. Preclinical Comparison of the Bloodbrain barrier Permeability of Osimertinib with Other EGFR TKIs. Clin Cancer Res. 2021 Jan 1;27(1):189-201. doi: 10.1158/1078-0432.CCR-19-1871.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Marley K, Gullaba J, Seguin B, Gelberg HB, Helfand SC. Dasatinib Modulates Invasive and Migratory Properties of Canine Osteosarcoma and has Therapeutic Potential in Affected Dogs. Transl Oncol. 2015 Aug;8 (4):231-8. doi: 10.1016/j.tranon.2015.03.006.</mixed-citation><mixed-citation xml:lang="en">Marley K, Gullaba J, Seguin B, Gelberg HB, Helfand SC. Dasatinib Modulates Invasive and Migratory Properties of Canine Osteosarcoma and has Therapeutic Potential in Affected Dogs. Transl Oncol. 2015 Aug;8 (4):231-8. doi: 10.1016/j.tranon.2015.03.006.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hofman J, Sorf A, Vagiannis D, Sucha S, Novotna E, Kammerer S, Küpper JH, Ceckova M, Staud F. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. Drug Metab Dispos. 2019 Jul;47(7):699-709. doi: 10.1124/dmd.119.086975.</mixed-citation><mixed-citation xml:lang="en">Hofman J, Sorf A, Vagiannis D, Sucha S, Novotna E, Kammerer S, Küpper JH, Ceckova M, Staud F. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. Drug Metab Dispos. 2019 Jul;47(7):699-709.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kim NA, Hong S, Kim KH, Choi DH, Kim JS, Park KE, Choi JY, Shin YK, Jeong SH. New Preclinical Development of a cMet Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC. Pharmaceutics. 2020 Feb 3;12(2):121.</mixed-citation><mixed-citation xml:lang="en">Kim NA, Hong S, Kim KH, Choi DH, Kim JS, Park KE, Choi JY, Shin YK, Jeong SH. New Preclinical Development of a cMet Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC. Pharmaceutics. 2020 Feb 3;12(2):121. doi: 10.3390/pharmaceutics12020121.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
